Sector: Health Care
Director information for NEOGENOMICS INC (data for year 2026)
| Name | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| Anthony ('Tony') Zook | [] | ["Audit and Finance Committee"] | 2026 | ||
| David Perez | Board Member and Chair of the Culture and Compensation Committee | 66 | ["40 years of global executive leadership experience","Led the growth and operations of several businesses","Experience in mergers and acquisitions","Retired president and CEO of Terumo BCT","Guided Terumo BCT through foreign ownership structures","Led multinational businesses and cross-cultural organizations","Transformed Terumo BCT to a global biomedical organization","Holds a BA in Political Science from Texas Tech University","Expertise in strategic planning, culture and talent development, succession planning, enterprise risk management, operations, compliance, and corporate governance","Strategy/Business Development / M&A","Risk Management","Public Policy / Regulatory Affairs"] | ["Audit and Finance Committee","Culture and Compensation Committee","Innovation, Pipeline & Technology Committee"] | 2026 |
| Dr. Marjorie Green | Board Member | 57 | ["Senior Vice President, Head of Oncology Global Clinical Development at Merck & Co. Inc.","Senior Vice President of Late Stage Oncology at Seagen","Licensed physician","Clinical researcher and physician treating oncology patients","Faculty member of The University of Texas MD Anderson Cancer Center","Approximately twelve years' experience in clinical research","Approximately fourteen years' experience as a clinical drug development leader","Expertise in selection and use of biomarkers for treatment","Strategy/Business Development / M&A","Human Resources/ Organizational Development","Legal / Governance / Business Conduct","Risk Management","Public Policy / Regulatory Affairs"] | ["Audit and Finance Committee"] | 2026 |
| Dr. Neil Gunn | Board Member and Chair of the Innovation, Pipeline and Technology Committee | 65 | ["Interim Chief Executive Officer of Genetic Signatures","Chief Executive Officer of IDbyDNA","President of Roche Sequencing Solutions","Head of Global Business for Roche Molecular Diagnostics","Vice President Commercial Operations for CaridianBCT","Vice President of Commercial Operations - Americas for Novartis Diagnostics","Expertise in oncology diagnostics and next generation sequencing","Financial (Reporting, Auditing, Internal Controls)","Strategy/Business Development / M&A","Legal / Governance / Business Conduct","Risk Management","Public Policy / Regulatory Affairs"] | ["Audit and Finance Committee","Culture and Compensation Committee","Innovation, Pipeline & Technology Committee","Innovation, Pipeline and Technology Committee"] | 2026 |
| Felicia Williams | Board Member | 60 | ["Senior finance leadership roles at Macy's, Inc.","Interim Chief Financial Officer at Macy's","Senior Vice President, Controller and Enterprise Risk Officer at Macy's","Senior Vice President, Finance and Risk Management at Macy's","Director of Anywhere Real Estate","Director of Paycom, LLC","Director of Meridian Bioscience, Inc.","Summa cum laude graduate from Florida A&M University with a Bachelor of Science in Accounting","35 years of experience leading multinational corporations","Financial (Reporting, Auditing, Internal Controls)","Sales / Marketing","Risk Management","Public Policy / Regulatory Affairs"] | ["Audit and Finance Committee","Nominating and Corporate Governance Committee"] | 2026 |
| Jack Kenny | Board Member | 57 | ["Served as President, Chief Executive Officer and a Board Member of Meridian Bioscience, Inc.","Senior Vice President and General Manager of North America at Siemens Healthcare","Vice President and General Manager of the US region at Becton Dickinson","Held sales leadership positions at Leica Biosystems, Quest Diagnostics, Siemens Medical Solutions and Abbott Laboratories","Director of Quantum-SI, Inc. since May 2023","Member of DCN Diagnostics' private company board since March 2024","Director of Orasure Technologies since September 2024","Chair of the Board of Cleveland Diagnostics, Inc. since February 2026","BS in management systems with a focus in marketing from Kettering University","Over three decades of diverse, executive, commercial and operational experience","Strategy/Business Development / M&A","Sales / Marketing","Risk Management"] | [] | 2026 |
| John ('Jack') Kenny | [] | ["Culture and Compensation Committee"] | 2026 | ||
| Lynn Tetrault | non-executive Chair of the Board; Non-Executive Chair of the Board | 63 | ["Over 30 years of experience in the healthcare sector","Former Executive Vice President of Human Resources and Corporate Affairs at AstraZeneca","Responsible for human resources strategy, talent management, executive compensation, and related activities","Practiced healthcare and corporate law at Choate, Hall and Stewart","Financial (Reporting, Auditing, Internal Controls)","Strategy/Business Development / M&A","Human Resources/ Organizational Development","Legal / Governance / Business Conduct","Risk Management","Sustainability","Public Policy / Regulatory Affairs"] | ["Audit and Finance Committee","Culture and Compensation Committee"] | 2026 |
| Michael Kelly | Chair of the Audit and Finance Committee | 69 | ["Former senior executive of Amgen","Founder & President of Sentry Hill Partners, LLC","More than two decades of executive experience in life sciences","Various strategic finance and operations positions","Experience managing and growing domestic and international organizations","Financial (Reporting, Auditing, Internal Controls)","Strategy/Business Development / M&A","Human Resources/ Organizational Development","Risk Management","Public Policy / Regulatory Affairs"] | ["Audit and Finance Committee","Culture and Compensation Committee"] | 2026 |
| Stephen Kanovsky | Board Member and Chair of the Nominating and Corporate Governance Committee | 63 | ["Over 25 years of legal and compliance experience in the global life sciences and pharmaceutical industry","Served as Deputy General Counsel and Chief Commercial Counsel of GE HealthCare","Involved with Clarient, Inc. prior to its acquisition by NeoGenomics","Financial (Reporting, Auditing, Internal Controls)","Strategy/Business Development / M&A","Sales / Marketing","Risk Management","Public Policy / Regulatory Affairs"] | ["Culture and Compensation Committee","Nominating and Corporate Governance Committee"] | 2026 |
| Tony Zook | Board Member and Chief Executive Officer; Director and Chief Executive Officer | 65 | ["Chief Executive Officer of a pharmaceutical company with global responsibilities","significant sales and marketing experience","operational and oncology experience","experience as a brand and marketing executive","Strategy/Business Development / M&A","Sales / Marketing","Legal / Governance / Business Conduct","Risk Management"] | [] | 2026 |
